| February 15 | Quiet period prior to the annual report begins |
| March 9 | Deadline for shareholder proposals for Annual General Meeting |
| March 15 | Annual report for 2016 |
| April 21 | Annual General Meeting |
| April 22 | Quiet period prior to the Interim report begins |
| May 4 | Interim report - 3 months 2017 |
| July 27 | Quiet period prior to the Interim report begins |
| August 10 | Interim report - 6 months 2017 |
| October 24 | Quiet period prior to the Interim report begins |
| November 7 | Interim report - 9 months 2017 |
Further information:
Gry Husby Larsen, General Counsel
Tel. no. (+45) 45 29 00 00, e-mail: investor@bioporto.com
About BioPorto
BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. Our pioneering product portfolio includes assays for underserved disease states such as NGAL for acute kidney injury. We sell our products in more than 80 countries through diverse sales channels and partners. BioPorto has its headquarters in Copenhagen, Denmark and is listed on the Nasdaq Copenhagen stock exchange.
